MSOs, Tech Firms, MPP, and Others Launch U.S. Cannabis Council

A new national cannabis advocacy organization, the U.S. Cannabis Council, announced its formation on Monday saying it “aims to advance social equity and racial justice, and end federal cannabis prohibition.” The organization, a 501(c)4 nonprofit, counts cannabusinesses, associations, and advocacy organizations among its founding members.

USCC Interim CEO Steven Hawkins, who also serves as executive director of the Marijuana Policy Project, described the organization as “a unified voice advocating for the descheduling and legalization of cannabis.”

“Legalization at both the state and federal level must include provisions ensuring social equity and redress for harms caused to communities impacted by cannabis prohibition.” – Hawkins, in a press release

Founding members of the organization include:

  • Acreage Holdings
  • Akerna Corp.
  • American Trade Association of Cannabis and Hemp
  • Association for Cannabis Health Equity and Medicine
  • BellRock Brands
  • Buckeye Relief
  • Cannabis Trade Federation
  • Canopy Growth Corporation
  • Columbia Care Inc.
  • Cresco Labs Inc.
  • Cronos Group
  • Culta
  • Curaleaf
  • DNA Genetics
  • Eaze
  • Flowhub
  • Global Alliance for Cannabis Commerce
  • Good Chemistry
  • The Grove Cannabis Dispensary
  • Headcount’s Cannabis Voter Project
  • Husch Blackwell
  • iAnthus Capital Holdings, Inc.
  • Jushi
  • Keef Brands
  • Lightshade
  • LivWell Enlightened Health
  • Marijuana Policy Project
  • Medicine Man
  • MedMen
  • Native Roots Cannabis Co.
  • 1906 New Highs
  • PAX Labs
  • PharmaCann
  • ProKure
  • Raw Garden
  • Schwazze
  • Scotts Miracle-Gro Company
  • Urbn Leaf
  • Veterans Cannabis Project
  • Vicente Sederberg LLP
  • Vireo
  • Wana

The organization has already received support from Oregon Rep. Earl Blumenauer (D), one of the staunchest supporters of federal cannabis law reforms and founder and co-chair of the Congressional Cannabis Caucus.

“We have a unique opportunity in the 117th Congress to advance cannabis reform, but we must remain united to create the change we know is possible,” Blumenauer said in a statement. “I look forward to welcoming the United States Cannabis Council to Washington, D.C. and working together toward meaningful policy change in the months and years ahead.”

Other members of the USCC includes Heather Azzi, general counsel for the Cannabis Trade Federation who will serve in that role for the USCC; Executive Assistant Brianca Hurley, who serves in the same capacity for the MPP; Deputy Vice President for Government Relations Chris Lindsay, who serves as a legislative analyst for the MPP; and Global Alliance for Cannabis Commerce Executive Director Randal Meyer as vice president of government relations.

End


Minnesota Bill Would Reschedule Cannabis to Let Patients Access Firearms

Minnesota Republican state Rep. Rod Hamilton is proposing a bill to reclassify medical cannabis in the state as a Schedule 2 drug in an effort to allow patients to legally keep their firearms under federal law, KSTP 5 reports.

Under federal law, medical cannabis patients lose their rights to own and possess firearms as cannabis remains a Schedule I drug under the Controlled Substances Act. Federal background check forms for firearms include a question about cannabis use and officials are able to search state databases to determine whether someone seeking to buy a firearm is also a registered patient in a medical cannabis program.

Hamilton, who has multiple sclerosis and is registered with the state’s medical cannabis program, said he has been unable to renew his permit to carry a gun or legally use a firearm to hunt due to federal law.

“We need to do this, along with other states like Oklahoma, to get the attention of Congress in Washington, D.C. It needs to change at the federal level and here so people can legally get their gun permits renewed and so they can hunt with family and friends and not be in violation of the law.  No one in the medical cannabis program wants to be in violation of the law.” – Hamilton to KSTP

According to the report, there are some 43,000 registered patients in Minnesota.

During his push last year to implement the reforms, which were stalled due to the coronavirus pandemic, Hamilton shared a letter from the U.S. Department of Justice Bureau of Alcohol, Tobacco, Firearms and Explosives that said, “there are no exceptions in Federal law for marijuana purportedly used for medicinal purposes, even if such use is sanctioned by State law.”

Hamilton has not yet introduced a bill for this session; however, last year’s measure included six Republican co-sponsors.

End


New Jersey Lowers Penalties for Psilocybin Possession

New Jersey Gov. Phil Murphy (D) signed a bill last week loosening penalties for the possession of psilocybin mushrooms, according to NJ.com.

The legislation lowers the possession of up to one ounce of psilocybin from a third-degree crime to a disorderly person offense but does not completely decriminalize mushrooms. However, instead of facing three to five years imprisonment, the longest jail sentence someone might serve for the substance would be six months and up to $1,000 in fines.

The idea to decriminalize psilocybin mushrooms was first proposed during cannabis reform negotiations after New Jersey voters approved the legalization of adult-use cannabis in November. Originally coupled with the cannabis legislation, the mushroom bill stalled negotiations, however, resulting in lawmakers splitting the issues into two bills and approving them separately from one another.

The psilocybin bill was the first drug reform bill signed this session by the governor, who has cited concerns around youth possession rules as a reason for not immediately approving the legislature’s cannabis legalization language.

Denver, Colorado was the first U.S. city to decriminalize psilocybin in 2019. Since then, other cities have taken up the issue, including Washington D.C. and, most recently, the state of Oregon passed a bill legalizing the medicinal use of psilocybin mushrooms. The ongoing movement is driven by broadening awareness of the medicinal uses of psilocybin in treating conditions like PTSD and new efforts to decriminalize entheogenic plants used by indigenous people, and others, for religious or spiritual purposes.

End


Australian Cannabis Company Loses $3.6M in Fraud Scheme

Australian cannabis company Cann Group Limited said it had lost $3.6 million in a “cyber security incident” involving payments meant for an overseas contractor related to work at its Mildura, Victoria facility.

The company, which trades on the ASX, said it discovered the breach on February 4 and it is “currently under investigation.” Cann said the payments to the contractor had been “received by an unknown third party as a result of a complex and sophisticated cyber fraud perpetrated against the company and its overseas contractor.” The contractor was unnamed in the Monday announcement.

“The Company is working with its bank to determine if any of the payments can be halted and if any of the funds involved are recoverable. The Company has notified its insurance brokers to determine if a claim can be made to recover any of the losses involved. Immediate action has also been taken to ensure the integrity of Cann’s IT systems.” – Cann Group Limited, Feb. 8, 2021, ASX Announcement

The firm said it remains in a “financial position to continue with its ongoing operations and projects,” including the Mildura facility, “irrespective of any funds being recovered.”

The company said it has alerted authorities in Australia, the Netherlands, and Hong Kong.

Last Christmas, Canadian cannabis company Aurora was the victim of a hack into its Microsoft Cloud software which led to company and employee data ending up for sale online.

Last year, cannabis point-of-sale system THSuite was targeted by hackers who ended up leaking 85,000 files from dispensaries throughout the U.S., including more than 30,000 records containing personally identifiable information.

Note: All figures in Australian dollars

End


Wisconsin Gov. Includes Adult-Use Legalization in Executive Budget Proposal

Wisconsin Gov. Tony Evers (D) is including cannabis legalization in his 2021-2022 budget proposal, MyStateline.com reports. The plan includes possession limits for residents up to two ounces and allows cultivation up to six plants but would allow non-residents to possess only a quarter ounce.

“Legalizing and taxing marijuana in Wisconsin – just like we do already with alcohol – ensures a controlled market and safe product are available for both recreational and medicinal users and can open the door for countless opportunities for us to reinvest in our communities and create a more equitable state. Frankly, red and blue states across the country have moved forward with legalization and there is no reason Wisconsin should be left behind when we know it’s supported by a majority of Wisconsinites.” – Evers, in a statement, via MyStateline

The Governor’s Office estimates that legal cannabis would generate more than $165 million annually starting in fiscal year 2023. The plan would earmark $80 million of cannabis-derived revenues for a new community reinvestment fund, including $30 million in social equity grants through the Department of Health Services, the Department of Administration, and the Department of Children and Families, $5 million in grants to underserved communities through the Wisconsin Economic Development Corporation, and more than $34 million for rural school districts, the Governor’s Office said. The remaining funds would be deposited into the state’s general fund.

Evers joins New York Gov. Andrew Cuomo, also a Democrat, in including adult-use reforms in the executive budget proposal. Democratic governors Ned Lamont in Connecticut and Lujan Grisham in New Mexico have also called for the reforms as lawmakers begin their 2021 legislative sessions.

In Wisconsin, both chambers of the legislature are controlled by Republicans. The leaders of both chambers, Devin LeMahieu in the Senate and Jim Steineke in the House, each received “F” grades from NORML due to their opposition to cannabis law reforms.

End


Former NFL Running Back Marshawn Lynch Launches Premium Blunt Brand

Former National Football League running back Marshawn Lynch on Thursday launched Dodi Blunts, a “premium, crafted cannabis brand-platform” that includes THCa “diamonds,” Mercury News reports.

The endeavor is a partnership between Lynch and Toronto, Canada-based 2nd and Goal Ventures.

Lynch, a four-time All-Pro and one-time Super Bowl champion with the Seattle Seahawks nicknamed “Beast Mode,” said “Fans who indulge in the first run of Dodi Blunts will experience the highest, richest potency from palm leaf-wrapped blunts infused with THCa diamonds presented in a reusable blunt tube.”

“And at the end of the day, the industry has the ability to raise up Black and Brown communities – and I intend to lift up those who I can. Plus, Dodi allows me to share with the world. What gets me (and my fam) in our zone, so others can get on my level.” – Lynch, in a statement, via 8 News Now

Prior to the Raiders moving from Oakland to Las Vegas, Lynch was caught off-camera lighting a blunt with the Al Davis Memorial Torch. Lynch said, “it was only right to send the Raiders off in a real Oakland way.” He retired before the team’s move to Vegas.

Jeff Goldenberg, 2nd and Goal founding partner, told 8 News Now that Dodi Blunts “challenges the traditional concept of ‘Game Day’ rituals and hopes to promote and normalize the relationship between sports and cannabis cultures.”

“Dodi Blunts is launching with the first athlete of Marshawn’s caliber at a moment in time when all the canna-stars are aligning: sports, culture and society, and politics and legalization,” he said in a statement.

Other former NFL players that have entered the cannabis space include Ricky Williams, Tiki Barber, Eugene Monroe, Joe Montana, and Marvin Washington.

Last year, the NFL announced it would no longer suspend players for positive cannabis results. Prior to the change, the league had the strictest cannabis policy among the four major U.S. sports leagues.

Following the announcement of Dodi Blunts, multiple mainstream media outlets including a Fox News subsidiary botched their reporting of the product launch, incorrectly suggesting that the “diamond-infused” blunts contained literal 24-carat diamonds.

End


Canada’s Regulated Cannabis Sales Finally Overtake Legacy Market

Licensed adult-use cannabis sales in Canada exceeded unlicensed sales for the first time during the third quarter of 2020  – by about $70 million, according to figures from Statistics Canada. Legal sales during the quarter reached $824 million while estimated illegal sales were $754 million.

Medical cannabis sales in the country were $146 million during the quarter, the lowest in the five quarters outlined in the government data.

Adult-use sales in the third quarter of 2020 far outpaced sales in the previous four quarters, overtaking quarter two sales by $194 million and doubling the $408 million realized in the third quarter of 2019, according to Statistics Canada data.

Unlicensed cannabis sales in Canada have been dropping steadily since the third quarter of 2019 when they were estimated at $935 million. In the following quarters, illegal sales fell to $890 million (Q4 2019), $842 million (Q1 2020), and to $801 million (Q2 2020).

In December, Ontario Auditor General Bonnie Lysyk released a report that found unregulated transactions comprised about 80% of the province’s sales, saying that products outside of the licensed market were of better quality than their regulated counterparts.

Industry activists and law enforcement agencies have contended that the lack of oversight on personal cultivation allowed under the nation’s medical cannabis laws also drove unregulated market products. About 34,000 Canadians have a license to grow cannabis for personal use.

George Smitherman, CEO of the Cannabis Council of Canada, told MJBizDaily that the quarter three figures illustrate “the success of one of the policy goals, which is bringing sales into the legal framework.” He added the “price decreases on key verticals of dry flower have been essential for transitioning many of those consumers.”

Note: All figures in Canadian dollars

End


Idaho Senate Passes Bill to Ban Cannabis Legalization Efforts

The measure to constitutionally ban any legalization of non-pharmaceutical psychoactive drugs in Idaho passed the Senate by a single vote on Wednesday, Boise State Public Radio reports. The proposal would still have to pass the House by two-thirds before moving to voters via a ballot initiative next year.

Republican State Sen. Scott Grown, the bill sponsor, has oft referred to the state as the “last foxhole” in the region without any form of legalized cannabis. Idaho is bordered by Washington state, Oregon, Nevada, and Montana – which have legalized cannabis for adult-use – and Wyoming and Utah, which have both legalized cannabis for medical use, although Utah’s program is extremely limited after lawmakers replaced a voter-approved initiative with a program of their own.

Earlier this month, House lawmakers from both sides of the aisle announced a plan to legalize medical cannabis in the state as activists are simultaneously running a ballot initiative campaign to get the reforms on ballots next year.

Hemp also remains Illegal in Idaho as lawmakers blocked a bill to legalize the industrial crop last year. Although, Gov. Brad Little (R) signed an executive order to explicitly allow hemp to be transported through the state after police arrested several truck drivers for hauling hemp.

If the constitutional amendment is approved by voters, the cannabis restriction would also apply to the state’s “right to try” law which allows terminally ill patients to be prescribed experimental drugs.

Some GOP members opposed the bill citing concerns that it would complicate the state’s constitution.

End


Alabama Senate Committee Advances Bill to Legalize Medical Cannabis

The Alabama Senate Judiciary Committee has passed a medical cannabis bill, picking up where they left off last year before the COVID-19 shut down, according to AL.com.

SB 46, known as the Compassionate Care Act, is essentially the same bill that passed the Senate last year and is sponsored by state Sen. Tim Melson (R), who has introduced medical cannabis bills for the last three years in Alabama. The bill would allow Alabamians with a select group of medical conditions to “register” for a medical cannabis card. The Act would set up an 11-member “Medical Cannabis Commission” that would oversee everything from seed to sale tracking, to registering patients and dispensing cannabis.

“It’s encouraging to see lawmakers making progress towards legalizing medical marijuana in Alabama,” Karen O’Keefe, state policies director for the Marijuana Policy Project, told Marijuana Moment. “It is morally wrong to continue to treat Alabamians who suffer from serious medical conditions as criminals for using a substance that is now legal in 36 states.”

Some of the provisions of the bill include sending 60 percent of the funds from a nine percent medical cannabis tax to the General Fund and 30 percent to studying the medical effectiveness of cannabis. Doctors would be required to take a four-hour continuing erducation course in order to recommend medical cannabis. Medical cannabis products would be limited to a narrow list, including capsules, lozenges, oils, suppositories, and topicals, eliminating all forms of edible and smokable/vapeable cannabis.

O’Keefe commented on the product restrictions: “We urge lawmakers to revise the provisions of the bill that create significant barriers for patients and their physicians.”

End


Fox News Subsidiary Botches Coverage of Marshawn Lynch Cannabis Brand

Former NFL running back Marshawn Lynch is not launching a cannabis product line infused with actual 24-carat diamonds, as was reported by several media outlets this week including Q13 FOX Seattle. Rather, Lynch’s Dodi Blunts product line will feature blunts infused with THCa crystals, a highly potent concentrate commonly called “diamonds” because of their rocky, crystalline appearance.

The media outlets in question appeared to center their reporting on the products’ “diamond-infused” description without looking further into what the term means in the context of the cannabis industry.

One article, attributed to “Q13 News Staff,” incorrectly asserted that Dodi Blunts will contain 24-carat diamonds and also tread a fine line between attempted humor and racial pandering, stating that Lynch, who is Black, is “bringing the bling to blunts.”

THCa diamonds are crystalline structures that form at the bottom of a THCa sauce extract. They are an incredibly potent form of cannabis concentrate.

“Our diamonds champion the highest, richest potency to uplift you to your peak. Gorgeous yet beastly, these THCa diamonds pack each blunt with super THC power.” — Product description excerpt, via Dodi Blunts

Dodi Blunts is the result of a recent partnership between the former NFL pro and Toronto, Canada-based 2nd and Goal Ventures. The products will be available at a selection of handpicked cannabis dispensaries throughout the San Francisco Bay Area.

End


Oregon Proposes Cannabis Social Equity Program

The Cannabis Equity PAC — a coalition of Oregon cannabis businesses, activists, and politicians — has announced the introduction of the Oregon Cannabis Social Equity Act, the group said in a press release.

HB 3112 would use cannabis tax dollars to help repair the damage done by the “War on Drugs.” Led by former state Rep. Akasha Lawrence-Spence, the group includes the NuLeaf Project, the Oregon Cannabis Association, the Oregon Retailers of Cannabis Association, the City of Portland, Urban League, and law students from Willamette University.

“We came together with a common purpose — to undo and repair some of the harm caused by cannabis criminalization on Black, Indigenous and Latinx communities in Oregon.This legislation uses cannabis tax revenue to invest in Oregonians who have been unjustly targeted for decades by law enforcement, in an effort to repair some of the generational harm done to their communities.” — Former Rep. Spence, in a statement

The bill has bi-cameral sponsorship and has three major provisions: direct investment into housing, job training and health care for Black, Indigenous, LatinX, and others convicted of cannabis crimes; the free and automatic expungement of eligible cannabis crimes; and social equity licenses that will have lower application fees, initial requirements. The bill also expands three license types to be more beneficial to small business owners.

“We’ve seen the harm to far too many families to not address this issue,” said Jeanette Ward Horton, the Executive Director of the New Leaf Project. “Cannabis convictions bring challenges that ripple through families and cause hardship for the children of children whose parents were disproportionately arrested. The loss of jobs, education grants, housing and more that can all stem from a minor cannabis conviction have impacted communities of color for generations. Today Oregon has the chance to undo some of that harm.”

Oregon already has a formal process to expunge cannabis crimes. However, according to Rep. Ricki Ruiz, a chief sponsor for the bill, “Less than 200 out of 28,000 Oregonians eligible for expungement were able to successfully complete the process in the past two years. We need to do better.”

“This bill provides us the path and the funding we need to efficiently remove previous cannabis crimes from people’s records and provide them the opportunity to repair their lives from the harm caused by cannabis criminalization,” he said. “It is a critical step toward restoring the health of these individuals and the communities where they reside.”

End


Report: Montana Has Highest Racial Disparity In Cannabis Arrests

In Montana, Black people are 9.6 times more likely to be arrested for cannabis possession than their white counterparts – the widest disparity in the U.S., according to American Civil Liberties Union data compiled by the Cincinnati, Ohio-based Joslyn Law Firm. Colorado had the lowest racial disparity with Black people 1.5 times more likely to be arrested for possession.

The report uses data from 2010 to 2018.

The largest racial disparities in cannabis possession arrests were in Pickens County, Georgia, where the arrest rate of Black people was 97.3 times higher than the white arrest rate – 321 white people were arrested for marijuana possession during the period analyzed compared to 31,243 Black people. DeKalb County, Alabama was the second-highest county for racial disparities in cannabis arrests at 44.6 to 1, the report found.

Nationally, Black people are 3.6 times more likely to be arrested for cannabis possession than their white counterparts – this despite studies that have found Black and white people use cannabis at similar rates.

In Kentucky, Black people were arrested for possession 9.4 times more often than white people, followed by Illinois, Iowa, and West Virginia at 7.5 times and 7.3 times each, respectively. The report does not include post-legalization data from Illinois, which was the first state to legalize cannabis via the Legislature in 2019. Illinois State Police and the governor expunged more than 500,000 cannabis-related criminal records on the final day of 2020.

Minnesota, North Dakota, South Dakota, and Wyoming all saw Black people arrested for cannabis possession at rates at least five times higher than white people, while Utah neared the mark at 4.9 times, the report found. Alabama, Connecticut, Delaware, New Hampshire, Maine Massachusetts, New Mexico, Kansas, Oklahoma, and Wisconsin all saw cannabis arrest rates four-times higher among Black people and of those states only Massachusetts has legalized sales and possession for adults. Idaho was close to the mark with cannabis arrest rates 3.9 times higher for Black people than white people int the state.

Michigan arrest rates were consistent with the national average of disparities, followed by Arizona, Georgia, Indiana, Louisiana, Ohio, Pennsylvania, Nebraska, Nevada New Jersey, Rhode Island, North Carolina, South Carolina, Tennessee, which reached a three-times rate of disparity but fell below the 3.6% average.

Arkansas, Maryland, Mississippi, Missouri, New York, Texas, and Washington state each saw arrest rate disparities between 2.1 and 2.9 times, while Alaska, California, Colorado, Hawaii, and Oregon saw disparate rates between 1.5 and 1.8 times. Three of those four states have legalized cannabis for adults.

End


Minnesota Democrats Ramp Up Cannabis Legalization Messaging

Minnesota Democrats are making the case for legalizing adult-use cannabis and expunging low-level cannabis crimes in the state, the Associated Press reports.

“The issue of legalizing cannabis, creating a fair, regulated marketplace, addressing the deep inequities in our criminal justice system, is a mainstream, bipartisan, broadly supported issue,” Democratic House Majority Leader Ryan Winkler said in a news conference earlier this week.

Joining other Mid-West states like South Dakota, Michigan, and Illinois, Minnesota would become the 16th state to embrace adult-use cannabis — but Democrats continue to face opposition from Republicans.

Republican Senate Majority Leader Paul Gazelka summed up GOP concerns: “We are focused on the Minnesota Priorities that balance the budget without raising taxes, safely reopen schools and businesses to recover our economy, and support families. I would not consider legalizing recreational marijuana as a Minnesota priority.”

Democratic Gov. Tim Winkler, who introduced an adult use cannabis bill last year ahead of the COVID-19 crisis, supports the push and has traveled around the state building momentum for adult-use cannabis for the past year and a half, the AP reports.

Other Democrats, like Rep. Rena Moran, say legalizing adult-use cannabis is key to breaking down systemic racism in Minnesota.

“Nowhere is the harm of the failed criminal prohibition felt more than for Black, Indigenous and people of color, which continue to experience outrageous disparities regarding enforcement of our current marijuana laws. Black Minnesotans are over five times more likely to be arrested for marijuana than those who are white. This is one of the worst disparities in the nation, and true even though both groups use it at similar rates.” — Rep. Moran, in a statement

End


Springbig Acquires BudTender Giving it Access to Canadian Retailers

Florida-based cannabis loyalty marketing and communications technology company springbig on Tuesday acquired Canada-based customer experience platform BudTender, creating what the company called “the most in-depth marketing, loyalty, and retention platform for cannabis dispensaries and brands.”

The terms of the deal were not disclosed.

Through the acquisition, BudTender will add over 200 clients to springbig’s existing customer base, increasing springbig’s market share to over 1,900 retailers throughout the U.S. and Canada.

Jeffrey Harris, springbig’s founder and CEO, said BudTender’s “vision and platform effortlessly complements springbig’s ongoing commitment to enhancing the cannabis retail and loyalty experience.”

“As the legal industry becomes increasingly sophisticated, brands and retailers will need to deploy more comprehensive customer retention and satisfaction solutions in order to stay competitive.” — Harris in a statement

Budtender CEO Jake Crow said the acquisition will “be a boon to cannabis retailers across North America” while enriching customer experiences and “will undoubtedly create a more modern cannabis industry.”

BudTender will integrate into springbig’s platform, allowing retailers and brands to access customizable customer surveys, weekly reports, an AI-powered feedback platform, 24/7 customer support, and track key performance indicators in real-time.

Last year, BudTender experienced 800% year-over-year store growth and 1,200% year-over-year revenue growth, the company said in a press release. Springbig, which was founded in 2017, develops custom cannabis industry loyalty software and boasts a 99% open rate on its targeted and personalized text message campaigns.

BudTender was already being used by more than 200 retailers in the U.S. and Canada.

End


Is Cannabis Good for Pain Relief?

Jointly is a cannabis wellness app that launched in April 2020. Jointly’s mission is to help people discover purposeful cannabis consumption. Purposeful cannabis consumption starts with the question: why do you use cannabis?

Many people use cannabis or CBD to manage their chronic pain. What does it look like to use cannabis or CBD to manage pain?

It could be a young woman who finds that a few puffs from a high THC vape pen at the onset of her migraines dramatically decreases her symptoms; or a hard-charging dad who uses CBD capsules to soothe his inflamed joints after a weekend of hiking with his grown children; or a cancer survivor with lingering nerve pain from chemotherapy who traded prescription opiates for a few puffs from a joint on the recommendation of her doctor.

Is Cannabis Good for Pain Relief?

Cannabis has been used to soothe pain for at least 5000 years. While cannabis may not be a mainstream pain reliever anymore, the majority of medical marijuana patients use cannabis to manage their chronic pain. Many feel it is highly effective.

For example, a 2019 survey of medical cannabis patients found that 65% of patients reported taking cannabis to relieve pain, and of that group, 80% reported that cannabis was “very or extremely helpful” for managing their pain.

A separate study conducted on 2987 people reporting their cannabis use and symptom relief found that cannabis benefitted numerous pain conditions including non-specified pain, headaches, back, muscle or joint pain, and gastrointestinal pain. These researchers noted that whole cannabis flower was associated with greater pain relief than any other type of product, and that higher THC levels were “the strongest predictors of analgesia.” Interestingly, CBD levels “were not associated with pain relief.”

Clearly, people feel that cannabis helps them manage their pain, but these data come from self-reported studies rather than clinical studies. What do clinical studies indicate about cannabis and pain?

What Does the Science Say About Cannabis and Pain?

The scientific literature holds seemingly contradictory findings. For example, despite the survey results above, many clinical studies indicate that cannabinoids have only weak analgesic properties.

A 2018 editorial published in the Journal of Applied Laboratory Medicine (JALM) states, “systematic reviews in acute pain are unequivocal in pointing out the lack of effectiveness of cannabinoids,” and “the reviews in chronic pain, mostly neuropathic, have arrived at similar conclusions, that cannabinoids and medical cannabis provide small analgesic benefit.”

How is it possible that people feel cannabis is highly effective at managing their pain, but clinical trials indicate that cannabinoids and cannabis are weak or ineffective analgesics?

Limitations of Cannabis Research

Decades of prohibition have created a situation where there simply aren’t many scientifically rigorous studies on cannabis and pain. As a result, “the current clinical debate continues to be driven, in large part, by variable analyses and perspectives of the same extant clinical trials.”

However, prohibition is only a piece of the puzzle. Many of the studies that found minimal benefit for pain used synthetic cannabinoids. Modern medicine and pharmacology follow a standard path of developing “safer and more efficacious drugs than plants themselves.”

However, there is evidence that isolated cannabinoids and synthetic cannabinoids may have less therapeutic benefit than the whole plant. For example, a 2018 review published in Pharmacotherapy states, “surprisingly, and as an unforeseen paradox to modern pharmacy…oral pharmaceutical grade cannabinoids show conflicting results in patients with chronic pain.” The authors of the review note that the evidence indicates that “oral cannabinoids are inferior when compared to…the cannabis plant.”

The editorial in JALM concedes, “it may be presumptuous to conclude that the major clinical effects of cannabis are derived solely from THC and cannabidiol (CBD). What becomes lost in the rhetoric…[is] the putative analgesic effects of terpenes and flavonoids.”

Beyond terpenes and flavonoids, there may be lesser-known cannabinoids in the whole cannabis plant that contribute to its pain-relieving effects. For example, a September 2020 article published in the medical journal Comprehensive Clinical Medicine notes that there are “hundreds of cannabinoid compounds…in the cannabis plant that variably activate CB1 and CB2 receptors.”

Part of the reason why clinical studies produce mixed results seems to be that these studies use isolated or synthetic cannabinoids, which seem to have less therapeutic benefit than the whole plant. In line with this idea, many surveys and self-reported studies indicate that cannabis flower is more effective than other types of products for relieving pain.

Supporting this notion, the National Academy of Sciences, Engineering, and Medicine found “substantial evidence that inhaled cannabis is effective for the treatment of chronic pain in adults.”

What Type of Pain Does Cannabis Help With?

There are three main pain systems: nociceptive pain, neuropathic pain, and central pain.

When your tissue is inflamed or injured, special pain detecting neurons called nociceptors transmit this information “via nociceptive pathways in the spinal cord to the brain.” Your brain interprets these signals and creates the subjective experience of pain.

In nociceptive pain, the nervous system is functioning normally and noxious stimuli like disease, inflammation or injury activate the nociceptors, “leading to organized responses that defend the tissue under threat and aid in its repair.”

Neuropathic pain is caused by “damage to sensory or spinal nerves, which send inaccurate pain messages to higher centers.” Neuropathic pain is characterized by spontaneous pain, allodynia (pain from normally innocuous stimuli), and hyperalgesia (excessive pain from something that would normally be mildly painful).

Central pain can be nociceptive or neuropathic, but it is caused by “dysfunction that specifically affects the central nervous system, which includes the brain, brainstem and spinal cord.” Fibromyalgia is the classic example of central pain. Basically, the central nervous system amplifies the pain signal, making the pain impossible to ignore.

Pain researchers discovered that in some circumstances, acute pain can lead to “hyperexcitability” of the nociceptors, essentially lowering the threshold needed to activate these pain neurons. This plasticity is unique: “unlike other sensory systems, nociceptive systems can sometimes undergo very long lasting, even permanent, enhancement of function following sufficiently intense activation.”

This process leads to “amplification of incoming [pain] signals,” and is a substantial part of neuropathic and chronic pain conditions. These chronic pain conditions are difficult to treat, but there is evidence that cannabis is effective for managing these types of pain.

A 2019 review of cannabis and pain found that oromucosal sprays are effective in reducing chronic and neuropathic pain caused by cancer, that inhaled cannabis flower is effective in reducing neuropathic pain in general, and that oral cannabis is effective for nociceptive pain.

Your Brain Creates Pain

During World War II, H.K. Beecher, a physician serving with the U.S. Army, observed that nearly three-quarters of severely wounded soldiers were “alert, responsive and not in shock…reported no to moderate pain [and] did not want pain relief medication.” Beecher’s observations were the first indication that the body has natural mechanisms of modulating pain, which we now know can either diminish or magnify pain.

Pain modulation refers to the process by which “the body alters a pain signal as it is transmitted along the pain pathway.” This innate pain modulation is an important part of how cannabis helps people manage pain. While endorphins (the body’s endogenous opioids) are known to play a role in pain modulation, preclinical studies have revealed that the endocannabinoid system plays an important role as well.

For example, when researchers injected rats with naloxone, an opioid receptor antagonist that blocks the effects of opioids, alongside a synthetic cannabinoid that exerts similar effects to THC, they observed effects “analogous to the effect of morphine, but these effects were not blocked by naloxone, indicating that these effects are mediated specifically through cannabinoid receptors.”

How Does the Endocannabinoid System Modulate Pain?

After an injury, the body produces endocannabinoids that reduce inflammation and pain signaling at the site of injury, which reduces pain.

As Kevin Hill, MD et al. write in their 2017 clinical review of cannabis and pain, “understanding the function of endogenous cannabinoids helps explain the efficacy of exogenous cannabinoids…in treating pain.”

The endocannabinoid system is made up of the CB1 (cannabinoid receptor 1) and CB2 receptors and the endogenous cannabinoids (anandamide and 2-AG) that bind to them. The CB1 receptors are found in the brain, nervous system, peripheral organs and tissue, while the CB2 receptors are found primarily on immune cells, although they are also found on bone, spleen and liver cells.

Research has shown that the endocannabinoid system “acts independently of the opioid pathway to control pain signaling, immune activation, and inflammation.” Scientists have found that CB1 receptors are “found in high concentrations in areas of the brain that modulate nociceptive processing, with a similar distribution to opioid receptors.”

There is evidence that both CB1 and CB2 receptors play a role in cannabinoid pain relief, but the CB1 receptor is thought to have the most direct influence on pain processing pathways.

How Does Cannabis Relieve Pain?

Both cannabinoids and opioids relieve pain through a mechanism that “blocks the release of pain-propagating neurotransmitters in the brain and spinal cord.” Activating the cannabinoid receptors “by endogenous or extraneously administered cannabinoids” inhibits pain signals and neurotransmitter release locally, at the spinal level and at the supraspinal level.

As Kevin Hill, MD et al. write in their clinical review, due to the complex ways that the endocannabinoid system modulates pain, “the biologically hypothesized rationale for cannabinoid administration is whole-body exposure to exogenous cannabinoids to turn on pain inhibition.”

There is also evidence that when the endocannabinoid system is activated, it downregulates neuronal hyperexcitability. If you recall, this hyperexcitability of neurons is a primary factor involved in the development and maintenance of chronic pain and neuropathy.

How Does CBD Relieve Pain?

There are a variety of mechanisms by which CBD can help people manage pain. While CBD doesn’t bind to cannabinoid receptors, it does increase the levels of anandamide, the endocannabinoid that binds to CB1 receptors (like THC). As established, the CB1 receptors play an important role in pain modulation.

However, the effects of CBD on chronic pain “are likely due to modulation of multiple non-endocannabinoid signaling systems.”

For example, CBD “enhances the activity of [GABA] receptors,” which can dampen pain signals as they enter your brain. CBD is also “a potent antioxidant.”

Additionally, “the pharmacodynamic profile of CBD resembles those of many currently prescribed treatments for neuropathic pain,” and research has demonstrated that CBD has a marked anti-inflammatory effect in animals and in in vitro experiments. At present, the research into how CBD affects inflammation in humans is “limited and inconclusive.”

Cannabis Makes Pain More Tolerable?

Many factors can affect how pain is experienced: your emotional state, your degree of anxiety, whether you are distracted or focused on the pain, your expectations about the pain, etc.

Experimental studies on cannabis and pain indicate that cannabis increases the threshold at which participants feel pain, and decreases the unpleasantness of pain, but does not reduce the intensity of pain.

A separate study drew the conclusion that cannabis affected only one of three subjective measures of pain: bothersomeness. The other two measures were pain intensity and a McGill Pain Questionnaire.

These findings are important in understanding why cannabis is such an effective tool for managing pain. While cannabis may not decrease the intensity of pain in the same way opioids do, it makes pain more tolerable — and also does not seem to increase sensitivity to pain in the way opioids do.

Cannabis has the ability to affect “the emotional component of pain” by boosting mood, reducing symptoms of anxiety or depression, and “offering some degree of dissociation from physical symptoms.”

According to the biopsychosocial model, pain is not simply a biological process, but one that involves a person’s psychology and larger social network. If pain is less bothersome, it may be psychologically easier to tolerate and have less of a negative impact on well-being. Please note this information is for educational purposes only, and any changes to your pain management strategy should be discussed with your doctor.

Curious if cannabis or CBD can help you manage pain?

Use Jointly to Manage Pain with Cannabis and CBD

With Jointly, you measure how well a cannabis product helps you achieve your wellness goals, including pain management.

As you record how well a product helps you manage your pain, Jointly helps you track the 15 factors that can impact your results so that you can enjoy your ideal experience every time and minimize any side effects.

Jointly users who have optimized their cannabis consumption by reporting at least 10 cannabis sessions are feeling 38% better.

Download the Jointly app today and start accomplishing your wellness goals with cannabis and CBD!

End


Bloom & Kool logo comparison

Big Tobacco Firm Sues Cannabis Brand Over Trademark

Kool cigarette maker ITG last week sued cannabis company Capna Intellectual, which does business as Bloom Brands, alleging it violated state and federal trademark law by stealing the cigarette brand’s logo, Law360 reports.

“In a transparent rip-off of ITG’s Kool marks, defendant advertises, promotes, distributes, imports, sells and/or offers for sale electronic cigarettes and oral vaporizers for adult smokers and adult tobacco consumers under the Bloom marks. The Bloom Marks contain interlocking ‘OOs’ which mimic the interlocking ‘OOs’ in ITG’s famous Kool marks.” – ITG in court filings via Law360

ITG said Bloom filed a trademark application with the U.S. Patent and Trademark Office in September 2019 seeking to register the similar mark for e-cigarette and vape sales. The company called Bloom’s acts deliberate “and intentionally carried out in bad faith, or with reckless disregard for or with willful blindness to ITG’s rights in the Kool marks, for the purpose of trading on ITG’s reputation and diluting the Kool marks.”

As the number of states legalizing cannabis has grown, so have trademark lawsuits aimed at businesses and brands. Last November, Ferrera Candy Co. – the makers of Nerds candy – filed a lawsuit against Tops Cannabis for their Medicated Nerds Rope parody product. The “Woodstock” name is the subject of a long running court battle between Woodstock Ventures LLC, which owns the rights to the festival and seeks to use the name to brand cannabis products and Woodstock Roots LLC, which secured trademark registration for the name to sell non-cannabis smokers’ products in 2013.

Other well-known national brands, including Citibank, Gorilla Glue, and Tapatio Foods – makers of the hot sauce – have sued cannabis companies for infringement or demanded that the stop using the moniker.

The ITG Brands LLC v. Capna Intellectual case was filed in the U.S. District Court for the Central District of California.

End


GW Pharmaceuticals Will Be Acquired for $7.2 Billion

United Kingdom-based GW Pharmaceuticals Plc will be acquired by Jazz Pharmaceuticals Plc in a $7.2 billion cash-and-stock deal, MarketWatch reports. The deal, announced this week, is expected to close sometime in the second quarter of 2021 in hopes of boosting first-year profits after the close and in order to drive additional revenue growth.

GW Pharmaceuticals’ pre-market stock prices soared 46% following the announcement.

GW Pharma is the manufacturer of Epidiolex, an oral solution which in 2018 became the first cannabis-based medication to receive FDA approval for patient use. Jazz Pharma is an Ireland-based biopharmaceutical company founded in 2003.

Epidiolex utilizes CBD to treat seizure symptoms. The medication was originally approved to treat Dravet syndrome, a rare and drug-resistant form of epilepsy, but in August 2020, the FDA also approved the drug as a treatment for seizures resulting from tuberous sclerosis complex.

Nawan Butt, the Portfolio Manager of The MEdical Cannabis and Wellness UCITS ETF (Europe’s first cannabis-focused ETF), said the deal could signal a significant shift in the international cannabis market.

“When [GW] started most global pharma companies were hesitant to do work with this plant ignoring centuries of evidence there were some health benefits,” Butt said. “Today could be a notable turning point… We don’t think this is the last deal we will see in the sector.”

End


Cannabis Legalization Bills Pre-Filed in New Mexico

Two cannabis legalization bills have been pre-filed in New Mexico, less than one week after Gov. Lujan Grisham called for the reforms during her State of the State address, KOB 4 reports.

The bills were filed by Democratic state Sen. Daniel Ivey-Soto and Republican Cliff Pirtle on Monday. The measures would both, essentially, do the same thing but differ on operational and enforcement details.

If approved, Pirtle’s bill calls for industry rules and regulations to be promulgated no later than September 1 with licenses manufacturing expected to be issued by Sept. 1, 2022 and cultivation licenses by June 1, 2022, according to the bill text. The proposal also allows local control and would allow social-use where approved. The measure includes provisions common in other states with adult-cannabis laws, including a ban on edibles that could appeal to children, testing, advertising bans, and limits on how far dispensaries must be from school, churches, parks, playgrounds, and youth centers.

The measure includes expungement provisions for cannabis-related crimes that would be legal under the new law.

Ivey-Soto’s proposal includes many of the same safeguards as the Republican’s plan but also would establish a Medical Cannabis Assistance Fund for low-income medical cannabis patients funded by cannabis taxes. The measure aims for an industry launch date of Jan. 1, 2022. The proposal sets possession limits at 2 ounces of flower and 16 grams of concentrates.

Both laws keep intact provisions of the state’s medical cannabis law that allow for home cultivation.

Both bills were sent to the chamber’s Taxation, Business and Transportation Committee.

End


Cannabis Grow Tech Company Agrify Lists on Nasdaq

Cannabis industry software company Agrify last week began trading on the Nasdaq under the “AGFY” symbol after completing a $54 million initial public offering. The IPO, which closed February 1, priced 5,400,000 common stock shares at $10 per share.

Maxim Group LLC and Roth Capital Partners acted as joint book-running managers for the offering.

Since the listing, Agrify has seen its shares as high as $15, and as low as $10.59.

“This is an incredible step forward to solidifying Agrify’s foothold in the indoor agriculture and tech space,” Agrify president and CEO Raymond Nobu Chang said in an interview with Green Market Report.

“We look forward to empowering a generation of modern growers to achieve better consistency and quality through the understanding that cultivation techniques must evolve to meet the market’s future needs.” – Nobu Chang to Green Market Report

The company does not cultivate, come in contact with, distribute or dispense cannabis or any cannabis derivatives that are currently prohibited under U.S. federal law. Its cultivation solutions can be used by indoor cannabis cultivators.

Agrify, based in Burlington, Massachusetts, reported 2019 net revenues of $4 million, which grew to $7.7 million for nine months ending September 30, 2020, according to Green Market Report, with net losses for those nine months of $8.5 million.

In their Securities and Exchange Commission filing outlined by Green Market Report, the company said they expect to “recognize revenue of approximately $40 million in 2021 and the rest gradually thereafter.”

“As of December 31, 2020,” the company said, “we have $105 million of carefully vetted potential sales opportunities (which we refer to as our qualified pipeline). Of this, $78 million of the qualified pipeline was generated through our company directly and $27 million through our Agrify-Valiant Joint-Venture.” The firm noted it planned to convert the pipeline into confirmed bookings over the next year.

End


Kansas Gov. Says Medical Cannabis Legalization Is Key to Expanding Medicaid

Kansas’ Democratic Gov. Kelly Chambers is proposing adopting medical cannabis in the state, and then using that money to pay for Medicaid expansion, the Associated Press reports. In a news conference held at a Kansas City health care software firm, the governor said she made the proposal to directly confront Republican claims that a Medicaid expansion would be too costly, a position that Kansas’ Republican party has held since the Obama administration.

Looking to make good on her campaign promises to expand Medicaid and legalize medical cannabis, the governor said at the news conference, “I’m hoping they will set aside the political party differences and recognize that both components of this bill, Medicaid expansion and medical legalization are extraordinarily popular among their constituents.”

Despite the endorsement of Democratic legislators and the governor’s enthusiasm, Republican leaders — who hold super majorities in both bodies of the legislature — have already come out against the plan. House Majority Leader Dan Hawkins told the AP he thought Kelly was focused on “high hopes and pipedreams.”

“Governor Kelly envisions a Kansas where you can choose not to work and taxpayers will foot the bill for you to stay home and smoke supposedly medicinal marijuana.” — New Mexico House Majority Leader Dan Hawkins, in a text to the AP

The governor’s current budget envisions adding 165,000 users to the state’s Medicaid system by July 1, 2021. In its first half-year, she estimates the initial expansion would cost Kansas $19 million, while the federal government would spend $541 million on the program. She estimates, however, that the state could raise up to $50 million per year by expanding medical cannabis, thereby eliminating the GOP’s main objections.

End


Senate Democrats Announce Plan for Federal Legalization

Senate Majority Leader Chuck Schumer (D-NY) and Sens. Cory Booker (D-NJ) and Ryn Wyden (D-OR) announced yesterday the formation of a Senate coalition dedicated to the legalization of cannabis. Specifically, the group committed to releasing a draft discussion bill “in the early part of this year” that will focus on restorative justice reforms, reinforcing public health, and implementing “responsible taxes and regulations” aimed at ending federal prohibition.

The announcement comes on the heels of Democrats having re-taken control of both the Legislative and Executive branches of the federal government during November’s election.

Last year, for the first time ever, the Democrat-controlled House of Representatives passed the MORE Act, a stand-alone bill that would end the federal prohibition of cannabis; the GOP-controlled Senate, however, failed to even consider the legislation.

“The War on Drugs has been a war on people—particularly people of color. Ending the federal marijuana prohibition is necessary to right the wrongs of this failed war and end decades of harm inflicted on communities of color across the country. But that alone is not enough. As states continue to legalize marijuana, we must also enact measures that will lift up people who were unfairly targeted in the War on Drugs. We are committed to working together to put forward and advance comprehensive cannabis reform legislation that will not only turn the page on this sad chapter in American history, but also undo the devastating consequences of these discriminatory policies. The Senate will make consideration of these reforms a priority.  — Sens. Schumer, Booker, and Wyden, in a joint statement

Oregon Rep. Earl Blumenauer (D) — a co-chair and founding member of the Congressional Cannabis Caucus — praised the move and called the bill’s co-sponsors, “our champions in the Senate.”

“Last year, we moved heaven and earth to get a bill passed through the House with key criminal justice and restorative justice provisions, but Mitch McConnell blocked consideration,” Blumenauer said. “Now, new Senate leadership is prepared to pick up the mantle.”

Justin Strekal, the Political Director for NORML, said of the announcement, “We look forward to constructively engaging with Congressional leaders, other organizations, and those communities that have historically been most impacted by criminalization in order to ensure that we craft the strongest and most comprehensive bill possible to right the wrongs of the nearly a century of federal cannabis prohibition.”

The move was foreshadowed last week by the Senate Majority Leader during an interview with cannabis entrepreneur/former NBA star Al Harrington. During their talk, Sen. Schumer told Harrington that lawmakers planned to merge several pieces of cannabis legislation in their quest for enacting federal reforms.

End


Cannabis Training Curriculum for Doctors Announced By Healthcare Education Group

The Society of Cannabis Clinicians (SCC) — a 501(c)(3) non-profit made up of expert clinicians and researchers — is releasing a new clinical medical cannabis training curriculum for medical professionals. Twelve of the twenty two training courses will be available remotely starting February 8, 2021. SCC members will receive 20% off of all educational offerings.

A recent study conducted by the SCC showed that 56% of clinicians felt that there was adequate information available to ethically practice cannabis medicine; however, according to a study conducted with medical patients in Vermont, only 18% of patients reported that their provider was a good source of information on medical cannabis. This divide is an issue that the SCC has been working to reconcile since its founding in 1999. The SCC’s latest offering will provide clinicians with a multi-pronged approach to understanding cannabis medicine and clinicians will leave with tools for better serving medical cannabis patients.

In the new educational modules, clinicians and researchers will learn how to build medical cannabis treatment regimens personalized to patient needs. They will also get access to an in-depth look at the endocannabinoid system and how it relates to cannabis as an application for a wide variety of conditions.

“The endocannabinoid system is an integral component to many bodily functions, and we still have much to uncover about its impact on human health. The fact that medical professionals are not taught about this vital signaling system in their training is detrimental to our ability to accurately understand disease pathology and is a disservice to public health. The SCC’s commitment to teaching cannabinoid science is guided by a responsibility to provide the best evidence-based patient care.” — SCC Program Director Christine Milentis

Researchers and clinicians who are looking to engage with this new educational offering can access individual modules or full course packages on the Society of Cannabis Clinicians website. Each module is optimized for desktop and mobile, so it can be accessed from anywhere. People who sign up for SCC membership will receive a discount on courses and gain full access to the resources made available after joining.

The SCC is currently raising funds to support the development of this educational endeavor. Each module offers critical education that is missing from most health professional training schools and continuing clinical education programs. Membership and individual donations financially support the non-profit’s mission. The group is currently working to meet a new donation goal to continue bridging the gap between cannabis medicine and medical practitioners.

End


CannaSafe: Touring a Fully-Accredited Cannabis Testing Lab

In most states, the Cannabis that is purchased at licensed cannabis dispensaries/store has been through a series of cannabis testing to provide the information seen on the labels: cannabinoids, terpenes, and potency to name a few. The purpose of the testing is to provide the consumer with a safe product and that the product is labeled with accurate information.

This month, I had the opportunity to visit, tour, and chat with CannaSafe and their CEO, Aaron Riley, to chat all things cannabis testing and the cannabis industry. CannaSafe is California’s leading ISO accredited cannabis testing laboratory, located in Van Nuys.

About CannaSafe

“If you can dream it, grow it, craft it; we can test it,” is the CannaSafe motto. Though 2020 was quite the roller coaster year, CannaSafe made strides. In January, Aaron was promoted from president to CEO, and Bosco Ramirez came in from being president of Eurofins TestAmerica, to VP of Operations for CannaSafe.

Not only promotions and new roles, but 2020 was also the year that they moved to a new 25,000 ft² headquarters facility — which is nearly double the size of their previous lab — to accommodate the industry’s growing demand.

As I walked through the facility, I saw a diverse group of people, the CEO having genuine laughs with the employees, and the cannabis testing process in action. It was quite the science lab in there, but definitely warm and full of energy.

The Long Road to CEO

From a small town in Indiana, to a High Times feature at the age of 16, to the football fields at Jacksonville University in Florida, to a jail cell during his sophomore year in college — CEO Aaron Riley has made some head-turning moves towards his role in the cannabis industry. After moving briefly in a different direction at the age of 22 (as the owner of a car dealership), Aaron found his way back to the legal cannabis space with CannaSafe.

The Cannasafe Team

Longtime friend and colleague Antonio Frazier has been by Aaron’s side since their college days. Antonio (who was a recent guest on the Ganjapreneur.com Podcast) came in as CannaSafe’s Lab Manager and is now President of the company. Antonio and Aaron met playing football together, and now they are CannaSafe’s dynamic duo.

It wasn’t always easy, though. Aaron recruited Antonio over a two-year period. It was when Aaron purchased most of the company in 2016 that Antonio made the commitment to move his family from the East to the West Coast:

“Aaron visited me out-of-state and convinced me to leave home and come to California. He believed my skillset to be necessary for this new venture. The decision was made easy because Aaron supported my family and I through the transition. The passion from Aaron made this venture impossible to refuse.”

Today, the Cannasafe team consists of a diverse group of leaders and employers. The company employs about 150 people — 147 more than there were when the company launched about a decade ago.

“Our team is inspired, unafraid, and emboldened to speak up, bring ideas to the table and to be a conduit for transformative change,” Frazier said.

CannaSafe’s Hopes for the Future

Integrity is at the heart of CannaSafe’s mission: “It’s at the heart of who we are, and we stand firm to our mission and core values.”

CannaSafe is working on a safe products list, a list of companies doing it right, and to offer reliable products with legit testing results. The company is also committed to social equity, consumer education, and patient advocacy. Aaron sponsors expungement clinics like Social Equity LA and The Social Impact Center.

“We believe we can make things better by working within our communities and running our business with purpose,” he said.

Also coming soon — the CannaSafe Center of Excellence lab, which will be focused on CBD and edibles.

The company also focuses on hiring people with prior cannabis convictions so that they have an opportunity in the legal space — additionally, in many cases, such hires end up being the most qualified. Aaron feels obligated to create a plan positioning CannaSafe as a company that offers second chances.

As for expansion, CannaSafe is eventually headed to the state markets of Florida and Oregon.

Final Thoughts

When I asked Aaron for his insight/advice for current and new states, and for the future of cannabis testing, Aaron suggested that pesticides are going to be monitored much more heavily, organic grows are always best, and a compliance person is one of the most important people to have on your team. Consumer protection suits will be coming because there are some brands and labs not being transparent.

And for those seeking a second chance, Aaron stated: focus on social equity opportunities, research programs in the state, and the different license types. Be diligent, he said, and seek out resources because there are many that will help with paperwork and processes.

End


New Mexico Court Overturns Burdensome Cannabis Safety & Testing Rules

A New Mexico court has ruled in favor of a coalition of licensed medical cannabis producers and one medical cannabis patient authorized to grow at home, essentially overturning the state’s safety and labeling protocols adopted by the Department of Health (DOH) last year, according to the NM Political Report.

The group first sued the state on the grounds the new rules requiring heavy metal and pesticide testing were “arbitrary and capricious” and would result in high prices for patients. First Judicial District Court Judge Bryan Biedscheid did not rule on the “merits” of the new rules, only that the state did not follow proper procedures when adopting the changes. Namely, that the rules lacked “substantial evidence” and the DOH did not consult the Medical Marijuana Advisory Board when developing the program.

Although the original lawsuit did not ask for all the rules to be invalidated, the court took that extra step and invalidated the entire new batch of regulations.

“The Court hopes that its additional findings and conclusions provide some guidance to the Department on remand and avoid additional remands due to lack of substantial evidence,” Judge Biedscheid wrote.

Additionally, the ruling overturns producers’ ability to increase their plant count under certain circumstances and throws out a consumption area provision that, according to the report, no medical cannabis producer in the state had yet taken advantage of.

The Department of Health already had testing and labeling requirements in place prior to the new regulations, so the New Mexico cannabis industry will return to its previous testing and labeling standards. are still testing and labeling standards in New Mexico. However, it is unclear if the legislature or DOH will take the issue up again; the DOH said it was “aware” of the judge’s ruling and is currently “evaluating options.” The legislature, meanwhile, may be too busy looking forward to adult-use cannabis regulations in the state.

End